Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imeroprubart in active CIDP
NCT07032662Phase 2Recruiting
- Sponsor
- Immunovant, Inc.
- Start
- Mar 2025
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies
- Countries
- 30
01
Overview
Phase 2, randomised, double-blind trial in chronic inflammatory demyelinating polyneuropathy (CIDP) comparing Imeroprubart with Placebo (2 arms). Primary endpoint: Proportion of participants remaining Relapse-free at 24 weeks. Started Mar 2025; status: recruiting.
02
Drugs
IMVT-1402
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT07032662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07032662.